- Previous Close
0.3400 - Open
0.3300 - Bid 0.3350 x --
- Ask 0.3450 x --
- Day's Range
0.3250 - 0.3450 - 52 Week Range
0.1600 - 0.6650 - Volume
566,793 - Avg. Volume
1,625,218 - Market Cap (intraday)
189.675M - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings Date Feb 24, 2025 - Feb 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 24, 1999
- 1y Target Est
0.84
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.
dimerix.comRecent News: DXB.AX
View MorePerformance Overview: DXB.AX
Trailing total returns as of 12/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DXB.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DXB.AX
View MoreValuation Measures
Market Cap
189.67M
Enterprise Value
167.68M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
10.43
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.83%
Return on Equity (ttm)
-141.42%
Revenue (ttm)
583.48k
Net Income Avi to Common (ttm)
-17.08M
Diluted EPS (ttm)
-0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
22.14M
Total Debt/Equity (mrq)
0.82%
Levered Free Cash Flow (ttm)
-11.78M